An interventional study of Extended MRI in Glioblastoma, sponsored by Erasmus Medical Center. Recruiting at 4 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-14.
Sponsored by Erasmus Medical Center · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Glioblastoma with a site in Netherlands — 24 open to participants now, 33 under way, 5 of them phase 3. Glioblastoma · Netherlands.
Among the 92 studies in Glioblastoma with a site in Netherlands, this one is the 28th largest by planned enrollment of the 77 interventional ones that give a count, is one of 5 that started in 2025, is one of 15 with no phase, reaches primary completion later than 10 of the 32 other live ones, and was the 91st registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →24 of the 92 studies in Glioblastoma with a site in Netherlands are open now. Recruiting first, the newest first:
Erasmus Medical Center · Sites in Netherlands
Ages 18+
Telix Pharmaceuticals (Innovations) Pty Limited · Sites in Netherlands, Australia, Austria and 1 more country
Ages 18+
Nationwide Children's Hospital · Sites in Netherlands, United States, Australia and 3 more countries
Ages 1–21 · Healthy volunteers
Bayer · Sites in Netherlands, United States, Australia and 10 more countries
Ages 18+
Rigel Pharmaceuticals · Sites in Netherlands, United States, Australia and 4 more countries
Ages 12–39
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 24 · Phase 3 18 · Phase 4 1
First in 1999; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Median enrollment 76 across the 77 interventional studies, 325 across the 15 observational. Of the 53 that completed or were terminated, 18 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 92 have an industry lead sponsor. The 10 most frequent:
Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.
Erasmus Medical Center has 8 studies filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
10 of the studies in Glioblastoma with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05904119Phase 3European Organisation for Research and Treatment of Cancer - EORTCLomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study | 2027-09 |
| NCT03975829Novartis PharmaceuticalsPediatric Long-Term Follow-up and Rollover Study | 2026-11-24 |
| NCT07121842Erasmus Medical CenterGlioblastoma Imaging for the Detection of Tumor Progression Using APTw-CEST MRI | 2027-01 |
| NCT04868396Maastricht Radiation OncologyPatient-derived Glioma Stem Cell Organoids | 2027-01-01 |
| NCT05641220Erasmus Medical CenterBiopsy Versus Resection in Elderly Glioblastoma Patients. A Prospective Cohort Study. | 2027-01-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 92 studies in Glioblastoma with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, the invesigators look at how a new MRI technique (called amide proton transfer weighted (APTw) chemical exchange saturation transfer (CEST)) can improve treatment for brain tumors through early detection of tumor progression after radiotherapy and/or chemotherapy treatment.
An issue with the current treatment for patients with a brain tumor, is the inability to detect tumor progression early. An abnormality is seen on MRI scans taken shortly after treatment with radiotherapy in about 30% of patients.
This abnormality may be a sign that radiotherapy treatment has worked well and will disappear on its own after a while. However, an abnormality can also be a sign of active tumor tissue. Then it shows that the treatment has not worked well enough. When there is active tumor tissue, this is called 'tumor progression'. When there is an abnormality that disappears on its own after a while, there is no active tumor tissue. This is called 'pseudoprogression'.
Currently, there are two options to determine whether tumor progression or pseudoprogression has taken place: Do another brain surgery to see if the abnormality contains active tumor tissue or wait and have regular MRI scans until it is clear whether the abnormality goes away on its own.
Amide proton transfer weighted chemical exchange saturation transfer (APTw-CEST) imaging is a new MRI technique in which investigators can produce images that show the accumulation of protein. APTw-CEST has previously been shown to be able to distinguish tumor progression from pseudoprogression earlier than current standard MRI scans. However, these previous studies have drawbacks: they were either done with a small group of patients in 1 hospital, or with a 7 Tesla MRI scanner, a rare type of scanner not standard in hospitals, or done in animal models.
In this research project the investigators now want to prepare APTw-CEST for standard patient care for patients with glioblastoma in the Netherlands so that in the future APTw-CEST can be included as a standard scan during treatment. The investigators are doing this by introducing APTw-CEST MRI on the clinical MRI scanners of four different hospitals. Ultimately, the investigators want to use this to create national guidelines for measuring and viewing APTw-CEST MRI images for early detection of tumor progression.
Rationale:
A major issue with glioblastoma treatment is the occurrence of contrast enhancement after treatment with radiotherapy or chemoradiotherapy. This enhancement can be due to more tumor growth; called true progression. It can also be due to treatment-related effects; called pseudoprogression. Amide proton transfer weighted (APTw) chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) is a technique that indirectly images proteins and peptides in a tissue. Because these molecules are overexpressed in tumor tissue, APTw-CEST MRI has been shown to be good at distinguishing between true progression and pseudoprogression, which is important as they require vastly different responses. This technique shows promise to become an important biomarker in glioblastoma treatment, how-ever it currently lacks standardization, as studies are generally done in one center on MRI machines of one vendor.
This multi-center study will make APTw-CEST MRI a clinically usable biomarker for the detection of tumor progression in glioblastoma patients by providing acquisition and post-processing recommendations, as well as a threshold on APTw-CEST images that would allow a clinician to accurately distinguish between pseudoprogression and true progression, regard-less of where the images were acquired and with which system.
The underlying processes that make APTw-CEST a reliable biomarker for glioblastoma treatment response evaluation are not clearly known. Using other advanced MRI techniques (diffusion, perfusion) and O-(2-[18F]fluoroethyl-)-L-tyrosine Positron Emission Tomography (FET-PET), and correlating these images with the APTw-CEST images will give a better insight into these processes.
Primary Objective: Determine the optimal threshold on APTw-CEST images in a multi-center (4 academic institutes) multi-vendor (Philips, Siemens and GE) clinical trial, to distinguish tumor progression from treatment-related effects.
Secondary Objective(s):
Study design:
In this prospective cohort study, all clinical MRI scans will be extended with the APTw-CEST protocol. The patient receives their standard care and decisions will be made based on standard-of-care imaging. The APTw-CEST images and diagnosis from standard follow-up will be used to determine the threshold on APTw-CEST images that would most accurately distinguish between pseudoprogression and true progression early after treatment.
Additional advanced imaging (diffusion, perfusion, FET-PET) taken during the treatment and follow-up of the patient will be used to correlate areas of high APTw signal with other signals.
Study population: 120 patients diagnosed with or suspected of glioblastoma using molecular or histochemistry analysis or medical imaging respectively.
Intervention (if applicable): Each patient will have extensions to all MRI scans taken for the treatment and follow-up of glioblastoma. The APTw-CEST sequence will be added to all clinical scans, for an addition of 10-15 minutes of scan time.
Main study parameters/endpoints: Threshold on APTw-CEST images that accurately distinguishes between true progression and pseudoprogression in recently treated glioblastoma patients. The accuracy will be optimized using Receiver operating characteristic (ROC) curve analysis and the Youden index.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The clinical care of the patient group will not be altered. The APTw-CEST images will not be used to make any clinical decision. Patients will not have personal benefit from this study, and will have the burden of a prolonged scan time of 10-15 minutes. All further imaging used in this study; perfusion, diffusion and FET-PET will not be taken specifically for this study and will only be taken when clinically indicated, except in LUMC where the FET-PET will be added to standard-of-care. The addition of FET-PET in the patient group in LUMC is warranted as the long-term risks are negligible for this patient group, due to the median survival of 12-14 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The MRI protocol for every clinical MRI scan taken in follow-up is extended with 15 minutes.
Diagnostic Test: Extended MRI
The MRI protocol for every clinical follow-up MRI scan is extended with 15 minutes to add the APTw-CEST scan.
Determining the Threshold
Determine the optimal threshold on APTw-CEST images in a multi-center (4 aca-demic institutes) multi-vendor (Philips, Siemens and GE) clinical trial, to distinguish tumor progression from treatment-related effects.
Time frame: Until 1 year after the first MRI scan with the additional APTw-CEST added
Correlations with other MRI and PET scans.
Correlate APTw-CEST MRI to complimentary, advanced imaging parameters such as FET-PET, diffusion and perfusion MRI, and RANO criteria.
Time frame: Up until 1 year from the date of the first MRI scan with added APTw-CEST
Plan to share: Undecided
Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 24 months after the start.
Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 24 months is below that.
Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.